Although no single variant modifier allele has been linked so far to amelioration or exacerbation of the clinical phenotype when concomitant with a FH genotype, some variants have been previously reported in carriers of the dominant hypercholesterolemia mutations with low levels of LDL‐C (Brusgaard et al. Here, COG2 is linked to familial hypercholesterolemia.